Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS).

Zhang, Meilian; Xie, Wenhuo; Li, Jianbin; Zheng, Jiaping; Zhou, Yu

Zhang, Meilian; Xie, Wenhuo; Li, Jianbin; Zheng, Jiaping; Zhou, Yu.

Afiliação

Zhang M; Department of Ultrasound, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.
Xie W; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Li J; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Zheng J; Department of Rehabilitation Medicine, School of Health, Fujian Medical University, Fuzhou, China. zhengjp@fjmu.edu.cn.
Zhou Y; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fujian Medical University, Fuzhou, China. cfjsczy@fjmu.edu.cn.

Arch Womens Ment Health ; 27(1): 35-44, 2024 Feb.

Article em En | MEDLINE | ID: mdl-37831172

Assuntos

Farmacovigilância; Inibidores Seletivos de Recaptação de Serotonina; beta-Ciclodextrinas; Feminino; Gravidez; Humanos; Estados Unidos; Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos; Estudos Prospectivos; Pregnanolona/efeitos adversos; United States Food and Drug Administration; Combinação de Medicamentos

Palavras-chave

Antidepressants; Brexanolone; Pharmacovigilance; Postpartum depression

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores Seletivos de Recaptação de Serotonina / Beta-Ciclodextrinas / Farmacovigilância Limite: Female / Humans / Pregnancy País como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google